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Abstract
BACKGROUND: Rheumatic heart disease (RHD) is recognized as a heart disease that occurs as a result of 
sequelae in acute rheumatic fever (ARF), characterized by the occurrence of defects in the heart valves. The most 
common manifestation of childhood RHD is mitral regurgitation (MR). The role of inflammation and oxidative stress 
in RHD also involves several components consisting of carboxy-terminal pro-peptide of Type I procollagen (PICP) 
and carboxy-terminal pro-peptide of Type III procollagen (PIIICP). 
AIM: The aim of this study was to know whether PICP and PIIICP can be used to measure the severity level of mitral 
valve regurgitation.
METHODS: This research is considered as descriptive-analytic research, and using cross-sectional analysis. Forty 
RHD patients underwent echocardiographic examinations to measure Wilkin and effective regurgitant orifice area 
scores. Patients were classified into ARF without valve abnormalities, mild, moderate, and severe MR. PICP and 
PIIICP were with ARF through venous blood and ELISA was examined. Data were analyzed by employing SPSS 22 
with p = 0.05). Wilkins scores and PICP levels have a regression coefficient of 0.296 with a p-value of 0.032.
RESULTS: There was a significant difference in PICP level among the studied sample groups with a p = 0.012, 
(p < 0.05), with insignificant difference in PIIICP level among sample groups with a p = 0.083, greater than α = 0.05 
(p > 0.05). Wilkins scores and PICP level have a regression coefficient of 0.296 with a p = 0.032 (p < 0.05), while 
PIIICP level has a regression coefficient of 0.093 with a p = 0.568 (p > 0.05).
CONCLUSION: There is no significant increase indicated on PIIICP level, but PICP level indicates a significant 
increase in RHD group with severe mitral valve abnormalities. PICP can be used to measure the severity level of 
mitral valve regurgitation.
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Introduction
Rheumatic heart disease (RHD) becomes 
a major cause of heart valve disease worldwide and 
is a leading cause of cardiovascular death in children 
at developing countries [1]. According to the World 
Health Association Report [2], the annual incidence 
of acute rheumatic fever (ARF) in children (age 5–14 
years) reaches to 300,000–350,000. In addition, there 
are around 1.5% mortality rates of RHD sufferers with 
carditis annually [2]. The mitral valve was the most 
commonly affected part of the heart valve (±65–70%), 
followed by the aortic valve (±25%), while the tricuspid 
and pulmonary valves were rarely affected. The most 
common valve abnormality in children concerns with 
mitral valve regurgitation mitral regurgitation (MR) [3].
Group A beta-hemolytic streptococcus 
(GABHS) polysaccharides and cardiac valve 
glycoprotein have similarities that are both considered 
as N-acetyl glucosamine. This structural similarity 
(molecular mimicry) causes a cross-reaction between 
GABHS and heart valve tissue [4]. Heart valve tissue 
that was not originally an antigen (non-self-antigen) 
turned into an antigen (self-antigen), thereby triggering 
a response to humoral immunity [5] and cellular 
immunity which in turn triggers inflammation [6].
Inflammation and oxidative stress in RHD 
involve several components, including carboxy-terminal 
propeptide of Type I procollagen (PICP) and carboxy-
terminal propeptide of Type III procollagen (PIIICP) [7]. 
Increased serum of PICP and PIIICP has been found 
in various heart diseases such as cardiomyopathy, 
hypertensive heart disease, adult heart failure, and 
adult rheumatic mitral valve disease [8], [9], [10]. 
However, relevant studies were unfortunately limited to 
examining the levels of PICP, PIIICP in pediatric RHD 
patients, and the relationship between PICP and PIIICP 
levels to the severity of mitral valve regurgitation in 
pediatric RHD.
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Echocardiography serves as the gold standard 
to determine the severity of valve involvement in RHD. 
Nevertheless, such examination has been widely 
unavailable; thus, an alternative examination is proposed 
as a predictor of valve damage degree in patients with 
RHD. One developed method is the examination of 
biomarker remodeling of P1CP and PIIICP [11].
Based on this background, the researchers 
initiated to examine the relationship between increased 
carboxy-terminal propeptide of Type I and Type III 
procollagen (PICP and PIIICP) to the severity of mitral 
valve regurgitation in pediatric RHD patients.
Materials and Methods
This research is considered an observational 
analytic study with a cross-sectional method. In this study, 
there were four groups of cases, including pediatric RHD 
patients with mild, moderate, and severe mitral valve 
regurgitation and one group of patients with rheumatic 
fever who did not experience valve abnormalities. This 
research was conducted at Children Cardiology Clinic at 
General Hospital Dr. Saiful Anwar Malang and Biomedical 
Laboratory, Faculty of Medicine, Universitas Brawijaya. 
This research was conducted on July 2019 until fulfilling 
the number of collected samples in December 2019 with 
ethical clearance number 400/136/K.3/302/2018.
Sample collection
The study sample involved pediatric patients 
(aged between 5 and 17 years) who were diagnosed 
with RHD and underwent outpatient care at Children 
Cardiology Polyclinic. All study subjects had agreed 
and signed the research informed consent.
Sampling in this study employs a purposive 
sampling method with exclusion criteria for patients 
experiencing inflammation or other acute infections 
other than ARF or RHD.This research used formula 
Dahlan, 2010 [12].
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Sampling of peripheral blood was performed in 
the Clinical Pathology Laboratory (Central Laboratory) 
of RSSA by laboratory personnel. The blood volume 
administered in each study sample was 3 cc for 
ELISA examination. Blood was inserted into the EDTA 
vacutainer tube, stored in a cool box, and kept at a 
temperature of 4°C [13].
Echocardiography
Based on echocardiographic results, forty 
patients were diagnosed with RHD based on the 2012 
Echo World Heart Federation criteria by determining 
the severity of mitral valve regurgitation. Morphological 
mitral valve features are well-visualized on standard 
2D echocardiography. This research used Vivid-q 2D 
echocardiography [14].
The severity of mitral valve regurgitation 
is determined by transthoracic echocardiography. 
The severity level is divided into three which are: 
mild, moderate, and severe by utilizing quantitative 
and semi-quantitative methods based on the 
European Association of Echocardiography (2010) 
recommendations to assess valvular regurgitation 
(mitral and tricuspid regurgitation), by considering 
the value of effective regurgitant orifice area, volume 
regurgitant, and venous contracta. Inflammation which 
occurs in the mitral valve is echocardiographically 
assessed by administering the Wilkins Score.
The morphology of the mitral valve was 
assessed as described by Wilkins et al., based on 
a semiquantitative grading of mitral valve leaflet 
mobility, thickening, calcification, and subvalvular 
thickening, each on a scale of 0–4, with higher scores 
representing the more abnormal structure. The total 
echocardiographic score was obtained by adding 
the scores of each of these individual components. 
According to this system, a score of 0 would be a totally 
normal valve, whereas a score of 16 would represent an 
immobile valve with fibrosis involving the entire leaflet 
and subvalvular apparatus and severe superimposed 
calcification [15], [16].
Biochemical marker examination
The technique to measure PICP and PIIICP 
levels in this study is ELISA with a sandwich technique. 
PICP level was measured by ELISA paint kit of 
SEA570Hu, while PIIICP level was measured by paint 
kit of CEA963Hu [13].
Statistical analysis
The collected data were analyzed by employing 
SPSS 22 software and multiple linear regression 
analysis to determine the effect of PICP and PIIICP 
levels on the severity of mitral valve regurgitation in 
pediatric RHD patients.
Results
The characteristics of the study involving 40 
research samples are presented in Tables 1 and 2 
by age, height, weight, total Wilkin Scores, and sex, 
respectively. Based on Table 1, the data indicate that 
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the lowest mean age was found in the severe group 
of 9.7 ± 2.2 years and the oldest average age was 
found in the moderate group which was 12.7 ± 2.3. 
The researcher performed ANOVA indicating p = 0.148 
(p > 0.05), marking that there were no differences in 
age characteristics between groups.
Table 1: Characteristics of the study sample by age, height, 
weight, and total Wilkin score
Group Characteristic
Age Height Weight Wilkin score
Normal 10.2 ± 2.2 135.1 ± 13.4 32.7 ± 15.4 0 ± 0
Mild 11.4 ± 3.9 140.2 ± 15 38.2 ± 11.4 0 ± 0
Moderate 12.7 ± 2.3 140.2 ± 15.1 37.3 ± 21.4 1.6 ± 1.1
Severe 9.7 ± 2.2 140 ± 6.6 31.9 ± 6.1 2.7 ± 1.5
p-value 0.148 0.799 0.363 0.000
Likewise, the characteristics of height and 
weight obtained p-value of more than 0.05 (p > 0.05). 
The results of the test proved that there were no 
significant differences in the characteristics of age, 
height, and weight between the studied sample groups.
Table 2: Characteristics of study samples by sex
Group Sex p-value
Male (%) Female (%)
Normal 5 (55.6) 4 (44.4) 0.175
Mild 5 (38.5) 8 (61.5)
Moderate 5 (55.6) 4 (44.4)
Severe 1 (11.1) 8 (88.9)
Total 16 (40) 24 (60)
Table 2 shows that, based on the characteristics 
of total Wilkin score, p < 0.05 which indicates the 
difference in characteristics of total Wilkin score. Both 
normal and mild groups have the lowest total score. 
The highest total Wilkin score was found in the severe 
group.
Table 2 shows the characteristics of study 
samples by sex which clearly indicates that the majority 
of the study samples are female. The result of Chi-square 
test demonstrating p = 0.175 (p > 0.05) proves that there 
are no differences in sex characteristics between groups.
When compared among the mild, moderate, 
and severe mitral valve regurgitation in children with 
RHD, the data indicate that the highest average of PICP 
levels is found in the severe group, which are significantly 
different from the mild and moderate groups.
Based on the ANOVA test, Figure 1 shows 
that the p = 0.012, (p < 0.05). Thus, the researcher 
concludes that there are significant differences in PICP 
levels among the studied sample groups. 
Figure 2 shows that analysis using the ANOVA 
test indicates p = 0.083, which is greater than p = 0.05 
(p > 0.05). Therefore, it is concluded that there is no 
significant difference in PIIICP level among the studied 
sample groups. 
Average PIIICP levels increase in the group 
of children with RHD, in mild, moderate, and severe 
group. However, increasing PIIICP levels do not occur 
significantly.
PICP level indicates a regression coefficient of 
0.034 with a p = 0.007 (p < 0.05), concluded that PICP 
level has a significant effect on the variable of valve 
regurgitation in children with RHD. Meanwhile, the level 
of PIIICP has a regression coefficient of 0.0–0.008 with 
a p = 0.303 (p > 0.05).
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Figure 2: PIIICP level of Mitral Valve Regurgitation in Children’s RHD
Wilkins score and PICP level have a regression 
coefficient of 0.296 with a p = 0.032 (p < 0.05), concluded 
that PICP level has a significant effect on Wilkins scores 
in children with RHD. Meanwhile, PIIICP level has a 
regression coefficient of 0.093, with a p-value of 0.568 
(p > 0.05).
Discussion
The sex distribution in this study demonstrates 
the prevalence of RHD cases which is higher in females 
than in males but does not show a significant difference. 
The proportion of RHD based on sex is slightly different 
from the proportion based on registry data in Australia 
(1997–2010), indicating approximately 65.8–71.1% 
of female. Although there are differences in numbers, 
similarity has been evident; emphasizing that female 
sex is higher than male.
The results of the study postulate that there are 
no significant differences in the characteristics of age, 
height, and weight among the studied sample groups. 
Thus, such finding indicates that the research sample is 
homogeneous among groups.
Cardiac extracellular matrix (ECM) consists of 
collagen Type I (85%) and Type III (11%). Type I and 
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Figure 1: PICP levels of Mitral Valve Regurgitation in Children’s RHD 
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III collagen are synthesized by cardiac fibroblasts. 
Cardiac fibroblasts are collagen-producing cells 
located in the human heart inhibited by mRNA cells for 
the formation of collagen I and III. Fibrillar collagen is 
synthesized as procollagen, further broken down by 
specific proteinases into carboxy (C) – and amino (N) 
– terminal propeptides. N-terminal Type I or Type III 
collagen propeptides (PINP and PIIINP) and C-terminal 
propeptides (PICP and PIIICP) are utilized as a Type 
I or III collagen synthesis marker. After splitting into 
propeptides, the triple helix chain will form fibers. 
During the inflammatory process in RHD, the released 
cytokines cause differentiation of valvular interstitial 
cells (VCIs) to activate myofibroblasts. VCIs are 
regarded as the most cells in valves producing ECM 
proteins, including collagen [10].
The role of carboxy-terminal propeptide of Type 
I (PICP) is released into the bloodstream during Type I 
collagen synthesis. Therefore, PICP is considered as a 
marker of Type I collagen synthesis. Likewise, PIIICP 
is released into the circulation during the synthesis 
of Type II collagen, which is 85% higher than PIIICP, 
causing PICP to be more significant than PIIICP.
A significant relationship to PICP in this study 
is similar to previous studies [10]. In the study, plasma 
carboxy-terminal propeptide of Type I (PICP) was 
indicated to increase concentration in MS and MR 
patients compared to the control groups. PICP levels 
are strongly related to the mitral valve area in MS. 
Whereas in MR, these parameters are related to left 
ventricular diastolic pressure and systolic diameter [10]. 
PICP level has a positive influence on the severity of 
valve regurgitation in children with RHD (p = 0.007, 
p < 0.05). This finding indicates that PICP level is 
beneficial to predict the severity of valve regurgitation.
The prior study emphasized that the ratio of 
Type I/III collagen in the mitral valve and aortic valve in 
10 patients with RHD, significantly increased (p = 0.001). 
The amount of collagen was higher in the mitral valve 
than in the aortic valve (p = 0.01), where the ratio of 
Type I/III collagen was lower in the normal mitral valve 
compared with the aortic valve (p = 0.001). Increased 
collagen in mitral and aortic valves for patients with RHD 
was mainly due to an increase in Type 1 collagen [17].
Type 1 and Type 3 collagen are found in 
cardiac tissue. Although Type 1 collagen is predominant 
in myocardium, Type 3 collagen is more specific to 
heart tissue [10], causing PIIICP to have no significant 
relationship to the degree of heart damage.
In addition, carboxy-terminal propeptides of 
Type III collagen (PIIICP) are not completely broken 
down during the conversion of pro-Type III collagen to 
Type III collagen, by considering the fact that it requires 
longer steps, removed during fiber degradation. 
Consequently, the ratio among the released number 
of Type III collagen, PIIICP, and PIIINP molecules is 
equivalent [18], causing an insignificant level of PIIICP.
The results indicate a significant difference in 
the total Wilkin scores among sample groups. Wilkins 
score includes four following parameters: Mitral valve 
thickening, valve mobility, valve calcification, and 
subvalvular thickening. Inflammatory parameters are 
positively related to biomarkers in the ECM [19], [20]. In 
this study, PICP and PIIICP levels escalate according to 
Wilkins score calculations.
Research about Wilkin score and mitral 
stenosis (MS) showed that in patients with MS, 
especially asymptomatic patients, the conjunction of 
the biomarkers score (BNP, tenascin-c, copeptin, and 
hs-CRP) and Wilkin’s score provided higher prognostic 
value [21].
Conclusion
There is no significant increase on PIIICP level; 
on the other hand, PICP level indicates a significant 
increase in RHD group with severe mitral valve 
abnormalities. PICP level also has a significant effect 
on Wilkins scores in children with RHD, highlighting that 
PICP level is advantageous to predict the severity level 
of valve regurgitation.
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